Biofrontera publishes interim report for the 3rd quarter of 2012
(Thomson Reuters ONE) -
Biofrontera AG /
Biofrontera publishes interim report for the 3rd quarter of 2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany - Biofrontera AG (DSE: B8F) has today published its interim
report for the third quarter of 2012 on the corporate webpage. The report
focuses on the company development; detailed financial figures are not being
published at the end of this period.
The overruling theme of the ongoing commercial year is the marketing of Ameluz®,
Biofrontera's prescription drug for the treatment of actinic keratosis. Ameluz®
was approved by the European Commission for EU-wide marketing and distribution
in December 2011. Since February 2012 Ameluz® is distributed in Germany through
Biofrontera's own sales force. Based on license and supply agreements formed
during the year, the medicinal product was also launched in Denmark, Sweden,
Norway, The Netherlands, the United Kingdom and Austria after the summer break,
partly after the reporting period. While first results of these countries are
still outstanding, the success is becoming apparent in Germany. Particularly in
recent months, sales of Ameluz® escalated.
The interim report provides detailed information on the progress of Ameluz®
marketing as well as other aspects of the corporate development. Revenues of the
first three quarters of 2012 amounted to TEUR 2,653, of which TEUR 1,550 were
one-time license payments.
The liquidity at the beginning of the year was TEUR 554, at the end of the
reporting period EUR 4.5 mln.
Since August Biofrontera's shares are trading on the regulated market of the
Frankfurt stock exchange (Frankfurter Wertpapierbörse) in addition to the
listing at the regulated market of the Düsseldorf stock exchange. Since
reporting obligations are identical, there is no change for Biofrontera. Share
liquidity, which is particularly relevant for major shareholders, increased to
an average daily trading volume of more than 26,000 shares.
About Biofrontera AG
Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The
Biofrontera group aims at attending and treating the skin, recognizing the
aesthetic needs of a person's visual reflection. Biofrontera is listed at the
regulated market of the Frankfurt stock exchange under the symbol B8F and the
ISIN number DE0006046113.
For further information please contact:
Anke zur Mühlen
Director IR & PR
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen(at)biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1659009]
Unternehmensinformation / Kurzprofil:
Datum: 19.11.2012 - 11:21 Uhr
Sprache: Deutsch
News-ID 204835
Anzahl Zeichen: 3592
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera publishes interim report for the 3rd quarter of 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
